Floatz logo

Immunoglobulin G1 [de-C-terminal-lysine], anti-(human epidermal growth factor receptor) (human-Mus musculus clone BCA101 ?1-chain), disulfide with human-Mus musculus clone BCA101 ?-chain fusion protein with peptide linker (GGGGS)3 fusion protein with 23-159-transforming growth factor ? receptor TGFBR2 (human), dimer

Epithelial Ovarian Cancer

Bicara Therapeuticsmonoclonal_antibodyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

244 Active assets in the Epithelial Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

Immunoglobulin G1 [de-C-terminal-lysine], anti-(human epidermal growth factor receptor) (human-Mus musculus clone BCA101 ?1-chain), disulfide with human-Mus musculus clone BCA101 ?-chain fusion protein with peptide linker (GGGGS)3 fusion protein with 23-159-transforming growth factor ? receptor TGFBR2 (human), dimer is also rated in:

EGFR AmplificationDormant
CC
Indicative ·
43 / 100
View asset →
anal canal squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
squamous cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →